671 related articles for article (PubMed ID: 15586226)
21. Familial and nutritional risk factors for p53 overexpression in colorectal cancer.
Freedman AN; Michalek AM; Marshall JR; Mettlin CJ; Petrelli NJ; Black JD; Zhang ZF; Satchidanand S; Asirwatham JE
Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):285-91. PubMed ID: 8722220
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma.
Saffroy R; Lelong JC; Azoulay D; Salvucci M; Reynes M; Bismuth H; Debuire B; Lemoine A
Br J Cancer; 1999 Feb; 79(3-4):604-10. PubMed ID: 10027337
[TBL] [Abstract][Full Text] [Related]
23. Have p53 gene mutations and protein expression a different biological significance in colorectal cancer?
Bazan V; Migliavacca M; Tubiolo C; Macaluso M; Zanna I; Corsale S; Amato A; Calò V; Dardanoni G; Morello V; La Farina M; Albanese I; Tomasino RM; Gebbia N; Russo A
J Cell Physiol; 2002 May; 191(2):237-46. PubMed ID: 12064467
[TBL] [Abstract][Full Text] [Related]
24. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
Shao ZM; Wu J; Shen ZZ; Nguyen M
Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
Ständer M; Peraud A; Leroch B; Kreth FW
Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
[TBL] [Abstract][Full Text] [Related]
26. Influence of tumor localization on the prognostic value of P53 protein in colorectal adenocarcinomas.
Diez M; Medrano M; Mugüerza JM; Ramos P; Hernandez P; Villeta R; Martín A; Noguerales F; Ruiz A; Granell J
Anticancer Res; 2000; 20(5C):3907-12. PubMed ID: 11268475
[TBL] [Abstract][Full Text] [Related]
27. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
Goodell V; Salazar LG; Urban N; Drescher CW; Gray H; Swensen RE; McIntosh MW; Disis ML
J Clin Oncol; 2006 Feb; 24(5):762-8. PubMed ID: 16391298
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic significance and clinic utility of serum and immunohistochemical cathepsin B levels in colorectal cancer].
Padilla D; Cubo T; Molina JM; García M; De la Osa G; Palomino T; Pardo R; Martín J; Arévalo E; Hernández Calvo J
An Med Interna; 2003 Oct; 20(10):521-5. PubMed ID: 14585038
[TBL] [Abstract][Full Text] [Related]
29. Comparative analysis of prognostic significance of molecular markers of apoptosis with clinical stage and tumor differentiation in patients with colorectal cancer: a single institute experience.
Ivanov K; Kolev N; Tonev A; Nikolova G; Krasnaliev I; Softova E; Tonchev A
Hepatogastroenterology; 2009; 56(89):94-8. PubMed ID: 19453036
[TBL] [Abstract][Full Text] [Related]
30. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.
Nasif WA; El-Emshaty HM; Tabll A; Elmasry SA; Attallah AM; Gad Elhak NA
Hepatogastroenterology; 2004; 51(58):1001-6. PubMed ID: 15239234
[TBL] [Abstract][Full Text] [Related]
31. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection.
Tang R; Yeh CY; Wang JY; Changchien CR; Chen JS; Hsieh LL
Ann Surg Oncol; 2009 Sep; 16(9):2516-23. PubMed ID: 19565285
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance in molecular detection of p53 mutation in serum of patients with colorectal carcinoma.
Ito T; Kaneko K; Makino R; Konishi K; Kurahashi T; Ito H; Katagiri A; Kushima M; Kusano M; Mitamura K; Imawari M
Oncol Rep; 2003; 10(6):1937-42. PubMed ID: 14534722
[TBL] [Abstract][Full Text] [Related]
33. Sex chromosome alterations associate with tumor progression in sporadic colorectal carcinomas.
Bottarelli L; Azzoni C; Necchi F; Lagrasta C; Tamburini E; D'Adda T; Pizzi S; Sarli L; Rindi G; Bordi C
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4365-70. PubMed ID: 17671117
[TBL] [Abstract][Full Text] [Related]
34. p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy.
Buglioni S; D'Agnano I; Vasselli S; Perrone Donnorso R; D'Angelo C; Brenna A; Benevolo M; Cosimelli M; Zupi G; Mottolese M
Am J Clin Pathol; 2001 Sep; 116(3):360-8. PubMed ID: 11554164
[TBL] [Abstract][Full Text] [Related]
35. Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas.
Forslund A; Kressner U; Lindmark G; Inganäs M; Lundholm K
Int J Oncol; 2001 Sep; 19(3):501-6. PubMed ID: 11494027
[TBL] [Abstract][Full Text] [Related]
36. [p53 mutations in sporadic colorectal cancers with microsatellite instability].
Huang J; Zheng S; Pan QR; Deng YC
Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(13):1130-3. PubMed ID: 12921629
[TBL] [Abstract][Full Text] [Related]
37. P53 mutations in colorectal cancer from northern Iran: Relationships with site of tumor origin, microsatellite instability and K-ras mutations.
Mahdavinia M; Bishehsari F; Verginelli F; Cumashi A; Lattanzio R; Sotoudeh M; Ansari R; Semeraro D; Hormazdi M; Fakheri H; Rakhshani N; De Lellis L; Curia MC; Cama A; Piantelli M; Malekzadeh R; Iacobelli S; Mariani-Costantini R
J Cell Physiol; 2008 Aug; 216(2):543-50. PubMed ID: 18330889
[TBL] [Abstract][Full Text] [Related]
38. DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study.
Bazan V; Migliavacca M; Zanna I; Tubiolo C; Corsale S; Calò V; Amato A; Cammareri P; Latteri F; Grassi N; Fulfaro F; Porcasi R; Morello V; Nuara RB; Dardanoni G; Salerno S; Valerio MR; Dusonchet L; Gerbino A; Gebbia N; Tomasino RM; Russo A
J Cancer Res Clin Oncol; 2002 Dec; 128(12):650-8. PubMed ID: 12474051
[TBL] [Abstract][Full Text] [Related]
39. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A
Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731
[TBL] [Abstract][Full Text] [Related]
40. SMAD4 as a prognostic marker in colorectal cancer.
Alazzouzi H; Alhopuro P; Salovaara R; Sammalkorpi H; Järvinen H; Mecklin JP; Hemminki A; Schwartz S; Aaltonen LA; Arango D
Clin Cancer Res; 2005 Apr; 11(7):2606-11. PubMed ID: 15814640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
